GHS-R1a is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Mark Stoyer, a nuclear chemist at the LLNL, later recalled, "We had intended to propose that name from Livermore, and things kind of got proposed at the same time from multiple places. I don't know if we can claim that we actually proposed the name, but we had intended it." In internal discussions, IUPAC asked the JINR if they wanted the element to be spelled "oganeson" to match the Russian spelling more closely. Oganessian and the JINR refused this offer, citing the Soviet-era practice of transliterating names into the Latin alphabet under the rules of the French language ("Oganessian" is such a transliteration) and arguing that "oganesson" would be easier to link to the person. In June 2016, IUPAC announced that the discoverers planned to give the element the name oganesson (symbol: Og). The name became official on 28 November 2016. In 2017, Oganessian commented on the naming:
==== Origins of molecular biology ==== Following the rise of classical genetics, many biologists—including a new wave of physical scientists in biology—pursued the question of the gene and its physical nature. Warren Weaver—head of the science division of the Rockefeller Foundation—issued grants to promote research that applied the methods of physics and chemistry to basic biological problems, coining the term molecular biology for this approach in 1938; many of the significant biological breakthroughs of the 1930s and 1940s were funded by the Rockefeller Foundation.
The discovery of the backdoor pathway to DHT biosynthesis in tammar wallaby pouch young prompted research into identifying and characterizing similar pathways in humans, leading to a better understanding of the regulation, metabolism, and therapeutic targeting of androgen biosynthesis in human health and diseases related to excessive or insufficient androgen biosynthesis when the classical androgen pathway could not fully explain the observed conditions in patients. Over the following two decades, several other distinct pathways have been discovered: the pathways that lead to the synthesis of 11-oxygenated androgens. Below is a brief selection of key events in the history of androgen backdoor pathway research:
A laboratory information management system (LIMS), sometimes referred to as a laboratory information system (LIS) or laboratory management system (LMS), is a software-based solution with features that support a modern laboratory's operations. They tend to be handled by inventory laboratory technicians. Key features include—but are not limited to—workflow and data tracking support, flexible architecture, and data exchange interfaces, which fully "support its use in regulated environments". The features and uses of a LIMS have evolved over the years from simple sample tracking to an enterprise resource planning tool that manages multiple aspects of laboratory informatics. There is no useful definition of the term "LIMS" as it is used to encompass a number of different laboratory informatics components. The spread and depth of these components is highly dependent on the LIMS implementation itself. All LIMSs have a workflow component and some summary data management facilities but beyond that there are significant differences in functionality. Historically the LIMyS, LIS, and process development execution system (PDES) have all performed similar functions. The term "LIMS" has tended to refer to informatics systems targeted for environmental, research, or commercial analysis such as pharmaceutical or petrochemical work. "LIS" has tended to refer to laboratory informatics systems in the forensics and clinical markets, which often required special case management tools.
== Dosage and administration == The drug and its generic counterparts are supplied in packages of 12, and available in two strengths: Each B&O Supprettes suppository #15 A contains 16.2 mg (1/4 grain) of belladonna and 30 mg (1/2 grain) of opium. Each B&O Supprettes suppository #16 A contains 16.2 mg of belladonna and 60 mg (1 grain) of opium. The usual dose is one suppository rectally once or twice daily PRN - (as needed), not to exceed four Supprettes in a 24-hour period. In the United States, B&O Supprettes is a Schedule II drug under the Controlled Substances Act of 1970; a written prescription is mandatory, and no refills are permitted. Refrigerated storage is preferable, but not required. Most pharmacies consider B&O Supprettes to be a "special order" item, and as such are not normally kept in inventory. Compounding pharmacies have the capability of producing a generic form of the medication, and can modify the dosage(s) of the active ingredients (for pediatric or elderly patients, and those with chronic kidney disease) or the carrier (usually substituting cocoa butter) to best meet the needs of the patient at the request of the prescriber.
Sources: en.wikipedia.org
== External links == Cabinet nod to cold chain centre : News Centre to reduce gaps in infrastructure :Agriculture Minister Cold chain draws (Indian) government attention- Industry Magazine What is NCCD :General knowledge essay Archived 2013-03-30 at the Wayback Machine India: Huge foreign investment opportunities in cold chain :Fresh Plaza news FDI in multi-brand retail is Heating up the Cold :FDI discussion Indian Cold chain industry to reach USD 11 billion by 2017 :Report India earned Rs 14000 crore (USD 2690 million) from export of horticultural produce 2012 :Report Archived 2019-02-22 at the Wayback Machine Effective Cold Chains Help Productivity :Report Faster movement of refrigerated vans on anvil :News System Standards and Guidelines for cold-chain infrastructure :Document Archived 2019-07-28 at the Wayback Machine Without Cooling, Most Modern Society Would Crumble :Forbes article How Cold-Chain Can Minimize Food Loss :Huffington Post Kinnow Cold Chain Study :Document Paradigm Shifts In India’s Agricultural Policy :Huffington Post Doubling farmers’ income by reducing food loss :News University of Birmingham appoints cold chain expert Kohli as professor :News" India to consider communal cooling hub potential :Report Deliberating Ways on Boosting EU -India Trade in Agri-products :Report CEO NCCD to demit office :News
== The "no waste" culture == Sake kasu can be considered as a part of the "no waste" culture in Japan. Sake kasu is the waste produced by sake production, and the Japanese decided to use it because they do not want to waste any of the ingredients. A lot of sake kasu is produced during sake production and a lot of sake kasu is considered as industrial waste and being discarded. In order to reduce the waste produced by the sake kasu in Japan, it is recycled for use in other products. Some breweries sell their sake kasu directly to restaurants or put it into packages sold in convenient stores and supermarkets.
Duane W, Hastings JW (1975). "Flavin mononucleotide reductase of luminous bacteria". Mol. Cell. Biochem. 6 (1): 53–64. doi:10.1007/BF01731866. PMID 47604. Fisher J, Spencer R, Walsh C (1976). "Enzyme-catalyzed redox reactions with the flavin analogues 5-deazariboflavin, 5-deazariboflavin 5'-phosphate, and 5-deazariboflavin 5'-diphosphate, 5' leads to 5'-adenosine ester". Biochemistry. 15 (5): 1054–64. doi:10.1021/bi00650a016. PMID 3207. Tu SC, Becvar JE, Hastings JW (1979). "Kinetic studies on the mechanism of bacterial NAD(P)H:flavin oxidoreductase". Arch. Biochem. Biophys. 193 (1): 110–6. doi:10.1016/0003-9861(79)90013-4. PMID 222213. Liu M, Lei B, Ding Q, Lee JC, Tu SC (1997). "Vibrio harveyi NADPH:FMN oxidoreductase: preparation and characterization of the apoenzyme and monomer-dimer equilibrium". Arch. Biochem. Biophys. 337 (1): 89–95. doi:10.1006/abbi.1996.9746. PMID 8990272. Lei B, Tu SC (1998). "Mechanism of reduced flavin transfer from Vibrio harveyi NADPH-FMN oxidoreductase to luciferase". Biochemistry. 37 (41): 14623–9. doi:10.1021/bi981841+. PMID 9772191. Tang CK, Jeffers CE, Nichols JC, Tu SC (2001). "Flavin specificity and subunit interaction of Vibrio fischeri general NAD(P)H-flavin oxidoreductase FRG/FRase I". Arch. Biochem. Biophys. 392 (1): 110–6. doi:10.1006/abbi.2001.2396. PMID 11469801. Ingelman M, Ramaswamy S, Niviere V, Fontecave M, Eklund H (1999). "Crystal structure of NAD(P)H:flavin oxidoreductase from Escherichia coli". Biochemistry. 38 (22): 7040–9. doi:10.1021/bi982849m. PMID 10353815. Eichhorn E, van der Ploeg JR, Leisinger T (1999).
zinc finger (ZF) A supersecondary polypeptide structural motif and DNA-binding domain occurring in many DNA-binding proteins, characterized by a series of non-adjacent amino acid residues which fold into a three-dimensional arrangement capable of coordinating one or more zinc ions (Zn2+) between them, thus stabilizing the fold into a definite structure that can interact specifically with other biomolecules such as nucleic acids or other polypeptides. There are many distinct classes of zinc fingers using different ligands and spatial arrangements to achieve coordination; in perhaps the most common variant, a short alpha helix is oriented antiparallel to a β sheet, with two histidine residues in the former and two cysteines in the latter forming the coordination complex. Zinc fingers bind DNA as the primary functional domain of many transcription factors.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
The standard approach is reversed-phase high-performance liquid chromatography, with purity reported as the relative area of the main peak. Ultraviolet detection near 214 nanometers is typical for peptides. Mass spectrometry is added to confirm identity rather than to quantify purity.